Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

43.63 +0.24 (+0.55%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
61 62 Next >
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified? 
Via Benzinga
Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends
 
Via Benzinga
Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits
In 2024, the Inflation Reduction Act limits out-of-pocket drug costs to $3,300 annually, with further reductions to $2,000 in 2025. 
Via Benzinga
Topics Economy
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... 
Via Benzinga
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
 
Via Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
 
Via Benzinga
Why NYSE:BMY qualifies as a good dividend investing stock.
Balancing Dividends and Fundamentals: The Case of BRISTOL-MYERS SQUIBB CO (NYSE:BMY). 
Via Chartmill
Bullish Continuation In '24? 3 Market Areas To Watch
This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
Via Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
There's more than meets the eye with all three of these dividend stocks. 
Via The Motley Fool
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Analyst Expectations For Bristol-Myers Squibb's Future
 
Via Benzinga
After A Bruising 2023, Bristol-Myers Squibb Forges A Risky M&A Strategy
Via Talk Markets
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
3 Dividend Stocks for Strong Returns in 2024 and Beyond
Investors should consider these three dividend stocks for 2024 and beyond, as they offer compelling yields and safety. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
7 Stocks Primed for a Spectacular Comeback in 2024
Although the usual suspects may carry confidence, these underappreciated comeback stocks might deliver the goods in 2024. 
Via InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely... 
Via Benzinga
3 Strong Dividend Stocks to Buy Early On in 2024
The markets are always looking forward, and you should, too. Here are three dividend stocks to buy now. 
Via The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
The major indexes boast big annual gains with the Dow at record highs. 
Via Investor's Business Daily
Topics Stocks
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch
On Wednesday, Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy... 
Via Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the... 
Via Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. 
Via InvestorPlace
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
H.C. 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.